论文部分内容阅读
目的探究不同剂量瑞舒伐他汀口服治疗冠心病心力衰竭的疗效。方法 70例冠心病心力衰竭患者,进行抽签分组分为对照组和观察组,每组35例。两组患者均服用瑞舒伐他汀作为固定治疗药物,对照组给药剂量为10 mg/d,观察组给药剂量为20 mg/d。治疗时长为1个月,治疗结束后对比两组患者的治疗效果以及不良反应发生情况(面色苍白、心率加快、呼吸不规则)。结果对照组显效患者12例(34.29%),有效患者13例(37.14%),无效患者10例(28.57%),治疗总有效率为71.43%。观察组显效患者19例(54.29%),有效患者14例(40.00%),无效患者2例(5.71%),治疗总有效率为94.29%。对照组的治疗总有效率明显低于观察组,差异具有统计学意义(P<0.05)。观察组不良反应发生率(8.57%)明显低于对照组(31.43%),差异具有统计学意义(P<0.05)。结论采用20 mg/d剂量的瑞舒伐他汀能够提升患者的治疗总有效率,在一定程度上能够减少不良反应的发生率,值得在临床中进一步借鉴及推广。
Objective To investigate the efficacy of different doses of rosuvastatin in the treatment of heart failure with coronary heart disease. Methods Seventy patients with coronary heart disease and heart failure were randomly divided into control group and observation group with 35 cases in each group. Patients in both groups took rosuvastatin as a fixed treatment. The control group received a dose of 10 mg / day and the observation group received a dose of 20 mg / day. The duration of treatment was one month. After treatment, the treatment effect and adverse reactions of the two groups were compared (pale, fast heart rate, irregular breathing). Results In the control group, 12 patients (34.29%) were effective, 13 (37.14%) were effective, 10 (28.57%) were ineffective and the total effective rate was 71.43%. There were 19 cases (54.29%) in the observation group, 14 cases (40.00%) in the effective group and 2 cases (5.71%) in the invalid group. The total effective rate was 94.29%. The total effective rate of the control group was significantly lower than the observation group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group (8.57%) was significantly lower than that in the control group (31.43%), the difference was statistically significant (P <0.05). Conclusion 20 mg / d dose of rosuvastatin can improve the total effective rate of treatment, to a certain extent, reduce the incidence of adverse reactions, it is worth further clinical reference and promotion.